Literature DB >> 29789902

Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile: a cross-sectional study in Japanese patients with stable angina pectoris.

Tetsuji Morishita1, Hiroyasu Uzui2, Akira Nakano1, Yoshitomo Fukuoka1, Hiroyuki Ikeda1, Naoki Amaya1, Kenichi Kaseno1, Kentaro Ishida1, Jong-Dae Lee1, Hiroshi Tada1.   

Abstract

The aim of this study was to evaluate the relationships among the traditional risk factors, lipid profile, and pentraxin-3 in stable angina (SAP). Plasma pentraxin-3 and serum LDL, HDL, and high-sensitivity CRP levels were measured in 163 SAP and 28 non-coronary artery disease (CAD) patients. Their relationships with five risk factors, hypertension (HT), dyslipidemia (DL), diabetes mellitus (DM), obesity (body mass index: BMI > 25 kg/m2), and high age (> 75 years), were evaluated. No significant difference was observed in the pentraxin-3 level between patients in SAP and in non-CAD [2.1 (1.4-3.5) ng/ml versus off 2.6 (1.6-3.8) ng/ml, P = 0.56). In SAP patients, pentraxin-3 levels decreased with more risk factors, according to the number of 3 traditional risk factors (HT, DL, and DM) and the number of 5 expanded risk factors (HT, DL, DM, obesity, and high age) (P for trend = 0.01 and 0.05, respectively). Pentraxin-3 showed a positive association with HDL (rs = 0.229; P = 0.050) and an inverse association with LDL (rs = - 0.224; P = 0.045). On multiple logistic regression, the number of 3 traditional risk factors was a significant predictor of pentraxin-3 levels (odds ratio = 0.444; 95% confidence interval  0.205-0.963, P = 0.040) in SAP patients. In SAP patients, the cardiovascular risk factor burden remained a negative impact on pentraxin-3 levels after multivariate analysis, suggesting that they have distinct roles in atherosclerosis.Trial registration: UMIN000023837.

Entities:  

Keywords:  C-reactive protein; Pentraxin-3; Risk factor; Stable angina pectoris

Mesh:

Substances:

Year:  2018        PMID: 29789902     DOI: 10.1007/s00380-018-1191-8

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  38 in total

1.  Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure.

Authors:  T Tsutamoto; T Hisanaga; A Wada; K Maeda; M Ohnishi; D Fukai; N Mabuchi; M Sawaki; M Kinoshita
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

2.  Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction.

Authors:  Junichi Matsubara; Seigo Sugiyama; Toshimitsu Nozaki; Koichi Sugamura; Masaaki Konishi; Keisuke Ohba; Yasushi Matsuzawa; Eiichi Akiyama; Eiichiro Yamamoto; Kenji Sakamoto; Yasuhiro Nagayoshi; Koichi Kaikita; Hitoshi Sumida; Shokei Kim-Mitsuyama; Hisao Ogawa
Journal:  J Am Coll Cardiol       Date:  2011-02-15       Impact factor: 24.094

3.  Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis.

Authors:  Giuseppe Danilo Norata; Patrizia Marchesi; Vivek Krishna Pulakazhi Venu; Fabio Pasqualini; Achille Anselmo; Federica Moalli; Irene Pizzitola; Cecilia Garlanda; Alberto Mantovani; Alberico Luigi Catapano
Journal:  Circulation       Date:  2009-08-10       Impact factor: 29.690

4.  Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality.

Authors:  S Frantz; S Störk; K Michels; M Eigenthaler; G Ertl; J Bauersachs; C E Angermann
Journal:  Eur J Heart Fail       Date:  2008-03-17       Impact factor: 15.534

5.  Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells.

Authors:  Giuseppe Danilo Norata; Patrizia Marchesi; Angela Pirillo; Patrizia Uboldi; Giulia Chiesa; Virginia Maina; Cecilia Garlanda; Alberto Mantovani; Alberico Luigi Catapano
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-24       Impact factor: 8.311

Review 6.  Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease.

Authors:  Carmine Zoccali; Francesca Mallamaci; Giovanni Tripepi
Journal:  Kidney Int Suppl       Date:  2003-05       Impact factor: 10.545

7.  Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.

Authors:  Takehiro Hashikata; Minako Yamaoka-Tojo; Ryota Kakizaki; Teruyoshi Nemoto; Kazuhiro Fujiyoshi; Sayaka Namba; Lisa Kitasato; Takuya Hashimoto; Ryo Kameda; Emi Maekawa; Takao Shimohama; Taiki Tojo; Junya Ako
Journal:  Heart Vessels       Date:  2015-08-13       Impact factor: 2.037

8.  C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany.

Authors:  Wolfgang Koenig; Hannelore Löwel; Jens Baumert; Christa Meisinger
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

9.  Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction.

Authors:  Monica Salio; Stefano Chimenti; Noeleen De Angelis; Fabiola Molla; Virginia Maina; Manuela Nebuloni; Fabio Pasqualini; Roberto Latini; Cecilia Garlanda; Alberto Mantovani
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

10.  Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.

Authors:  Satoshi Suzuki; Yasuchika Takeishi; Takeshi Niizeki; Yo Koyama; Tatsuro Kitahara; Toshiki Sasaki; Mina Sagara; Isao Kubota
Journal:  Am Heart J       Date:  2007-09-27       Impact factor: 4.749

View more
  2 in total

1.  Revealing the Common Mechanisms of Scutellarin in Angina Pectoris and Ischemic Stroke Treatment via a Network Pharmacology Approach.

Authors:  Zi-Qi Meng; Jia-Rui Wu; Ying-Li Zhu; Wei Zhou; Chang-Geng Fu; Xin-Kui Liu; Shu-Yu Liu; Meng-Wei Ni; Si-Yu Guo
Journal:  Chin J Integr Med       Date:  2020-05-22       Impact factor: 1.978

2.  [Research progress on the role of pentraxin 3 in polycystic ovary syndrome].

Authors:  Wei Wu; Jian Xu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-10-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.